We just announced that the Moderna COVID-19 Vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa. Read more: buff.ly/39i2cOp.. https://t.co/nCGl3hfhlU
We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.
Read more: buff.ly/3puVGK6.. https://t.co/YuLubU1tlx
We just announced the primary efficacy analysis in the Phase 3 COVE study for mRNA-1273, our COVID-19 vaccine candidate and that today, we plan to request an Emergency Use Authorization from the U.S. FDA & conditional approval from the EMA. Read more: buff.ly/2Jt56Fz.. https://t.co/36tpY0QeFl
Summary of our SARS-CoV-2 #vaccine (mRNA-1273) interim Phase 1 data. Read more: buff.ly/3bEUhZ9.. #mRNA https://t.co/BVbYuWTkOy
We just announced a longer shelf life at refrigerated temperatures for mRNA-1273, our COVID-19 vaccine candidate. Read more: buff.ly/3f2RE6V.. https://t.co/s0BSMtaifg
We just announced positive interim Phase 1 data for our mRNA vaccine (mRNA-1273) against novel coronavirus. Read more: buff.ly/3bEUhZ9.. https://t.co/w1MpUniTVh
Update: Moderna’s data for the Emergency Use Authorization request for mRNA-1273 has been submitted to the U.S. FDA.
We just announced that the FDA has authorized the Moderna COVID-19 Vaccine in the U.S. for emergency use to prevent COVID-19 in individuals 18 and over. The Moderna COVID-19 Vaccine has not been approved or licensed by the FDA. buff.ly/34oHMjW.. https://t.co/oNeB3DXazu
Read more in our press release here: buff.ly/2WjGoLr.. https://t.co/8JMVGIsxf1
We just announced that the first participant has been dosed in the NIH-led Phase 1 study of our #mRNA vaccine (mRNA-1273) against novel coronavirus buff.ly/33nqi5v.. https://t.co/LnJWYhAbkx
We just announced an expansion of our agreement with @BARDA for up to an additional $472 million to support our late stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. Read more: buff.ly/32XjxZV.. https://t.co/5bhmfEkQ5t
We just announced that we have shipped vials of mRNA-1273, the Company’s vaccine against the novel coronavirus, to the NIH to be used in the planned Phase 1 study in the U.S. investors.modernatx.com/news-releases/….. https://t.co/o7EoaYeQH1
Breaking: Moderna announces a supply agreement with the U.S. government to secure an initial 100 million doses of mRNA-1273 for up to $1.525 billion with option granted to U.S. government to purchase up to an additional 400 million doses
We just confirmed that the Company is engaged in discussions with the government of South Korea to potentially provide 40 million or more doses of the Moderna COVID-19 Vaccine. Read more: buff.ly/3hq48Xk.. https://t.co/mPBLDTyMYE
We just announced the U.S. gov't has exercised the 1st option for an additional 100 million doses of our COVID-19 vaccine candidate, which will be delivered in Q2 2021. Read more: buff.ly/37ag2kD.. https://t.co/l2Cs0qYZcM
We just announced that we have completed enrollment of 30,000 participants for the Phase 3 COVE study of mRNA-1273, our vaccine candidate against COVID-19. Read more: buff.ly/3oilbh2.. https://t.co/qDEKn0o4Op
Update: The European Medicines Agency has received Moderna’s application for conditional marketing authorization of our COVID-19 vaccine
This morning, we announced a U.S. supply update for the Moderna COVID-19 Vaccine, reporting that 30.4 million doses have been supplied to the U.S. Government to date. We remain on track deliver 100 million doses to the USG by end of March 2021. Read more: buff.ly/39gKZVt.. https://t.co/fh5hAHnCf2
We just announced that Health Canada has authorized the Moderna COVID-19 Vaccine in Canada. Read more: buff.ly/3rrsvIL.. https://t.co/3GKVWrXEs1
We just announced that the UK’s MHRA has approved our mRNA vaccine against COVID-19 for use. The UK government also secured an additional 10 million doses of the COVID-19 Vaccine Moderna. Read more: buff.ly/3omOnDg.. https://t.co/SCTomqdAtl
We also announced that out of an abundance of caution, we are launching a clinical program to boost immunity to emerging variants. Learn more: buff.ly/39i2cOp..